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Abstract
Host factors that microbial pathogens exploit for their propagation are potential targets for therapeuic countermeasures.
No host enzyme has been identified whose genetic absence benefits the intact mammalian host in vivo during infection
with Mycobacterium tuberculosis (Mtb), the leading cause of death from bacterial infection. Here, we report that the dsRNA-
dependent protein kinase (PKR) is such an enzyme. PKR-deficient mice contained fewer viable Mtb and showed less
pulmonary pathology than wild type mice. We identified two potential mechanisms for the protective effect of PKR
deficiency: increased apoptosis of macrophages in response to Mtb and enhanced activation of macrophages in response to
IFN-gamma. The restraining effect of PKR on macrophage activation was explained by its mediation of a previously
unrecognized ability of IFN-gamma to induce low levels of the macrophage deactivating factor interleukin 10 (IL10). These
observations suggest that PKR inhibitors may prove useful as an adjunctive treatment for tuberculosis.
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Introduction
In an era when the spread of antibiotic resistance has outpaced
the introduction of new anti-infectives, attention has turned to the
possibility of directing adjunctive anti-infective therapy against
temporarily dispensable targets in the host [1]. If a drug does not
act on the pathogen, the pathogen cannot become resistant based
on the usual mechanisms: impaired drug uptake or retention,
reduced drug activation, increased drug inactivation, or the
mutation, over-expression or bypass of the target. This notion has
lent increased interest to studying the biology of host-pathogen
relationships by identifying cellular (host) genes exploited by
pathogens (CGEPs) [2,3].
The first CGEPs for a mycobacterium were identified when an
RNAi screen confirmed the importance of phagocytic recognition
and uptake machinery for M. fortuitum infection of a cell line from
drosophila [4]. A CGEP for Mtb, the leading single cause of death
from bacterial infection, emerged with the demonstration that
protein kinase B (PKB; Akt) was required for optimal growth of
Mtb in primary human macrophages in vitro [5]. However, the
importance of this pathway in tuberculosis has apparently not
been tested in an animal model. More recently, RNAi screens
against all known kinases and phosphatases in a mouse
macrophage cell line [6] and against all genes in a human
macrophage cell line [7] identified numerous candidate CGEPs
for Mtb.
Classical macrophage activation protects the host from diverse
facultative or obligate intracellular pathogens, including Mtb. The
major inducer of classical macrophage activation is IFN-gamma
[8,9]. In activated macrophages, IFN-gamma co-induces tran-
scription of a major anti-mycobacterial effector enzyme, the Ca
2+-
independent isoform of nitric oxide synthase (iNOS) [10,11].
However, certain cytokines can prevent, suppress or reverse
macrophage activation. In order of their discovery, macrophage
deactivation factors include a glycoprotein secreted by tumor cells
[12], TGF-beta [13] and IL10 [14,15]. IL10 is produced not only
by T cells but also by macrophages themselves. IL10 antagonizes
not only macrophage responses to IFN-gamma but also the
production of IFNc by T cells [16].
The pathogenesis of tuberculosis depends on the host’s immune
response in two competing ways. The Th1 immune response and
ensuing macrophage activation restrain Mtb replication well
enough that immunocompetent people with a skin test indicative
of persistent infection face only a 5–10% chance of developing
clinically apparent tuberculosis. Yet survival of Mtb as a species
requires that immunopathology progress far enough in some of
those infected for host enzymes to liquefy lung tissue and generate
an infectious aerosol [17]. Once host-mediated immunopathology
is advanced enough to be recognized as active tuberculosis, it will
kill about half of those affected unless they are treated. Thus, to
survive as a species, humans must not only be able to activate their
macrophages in response to this widespread pathogen but also
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pathologic response [18].
A screen for macrophage clones whose expression of certain
genes was regulated by an expressed sequence tag library [19] led
us to explore dsRNA-dependent protein kinase (PKR) as a
candidate gene for affecting the cells’ response to infection with
Mtb (unpublished data). PKR is a widely expressed serine/
threonine kinase whose expression is enhanced in response to type
I IFN. Binding of dsRNA promotes PKR’s homodimerization
[20,21], autophosphorylation and activation [22]. PKR-depen-
dent phosphorylation of eukaryotic initiation factor 2-alpha
impairs protein synthesis, contributing to IFN’s antiviral actions
[23]. However, PKR has many other activators, including LPS,
IL1 and TNF-alpha [24,25], and substrates, including insulin
receptor substrate [26]. Despite PKR’s potentially widespread
actions, its genetic disruption appears to leave mice in good health.
Moreover, PKR
2/2 mice have displayed very limited phenotypes
upon challenge with some viruses and no phenotype with others
[27]. Thus, temporary inhibition of PKR is likely to be tolerable.
The foregoing observations encouraged us to study the course of
Mtb infection in PKR-deficient mice. PKR-deficient mice
sustained lower Mtb burdens and had less pulmonary pathology
than wild type mice. In seeking an explanation, we discovered that
PKR-deficient macrophages underwent more apoptosis than wild
type macrophages when infected with Mtb in vivo and in vitro,
and produced more iNOS and TNF-alpha in response to IFN-
gamma. In wild type macrophages, IFNc activated PKR. PKR in
turn mediated induction of the macrophage-deactivating factor
IL10. At the low levels induced by IFN-gamma, IL10 tempered,
without preventing, IFN-gamma-dependent macrophage activa-
tion. Thus, in the absence of PKR, macrophages were more fully
activated. These findings raise the possibility that a PKR inhibitor
could boost host immunity to serve as an adjunctive treatment for
tuberculosis and perhaps other infections.
Results
Impact of PKR Deficiency on Tuberculosis
To determine the impact of PKR deficiency on tuberculosis, we
compared the bacterial burden in Mtb-infected wild type and
PKR-deficient mice up to 168 days after low-dose infection by
aerosol (Figure 1A). The course of infection in the lung was
indistinguishable between the two strains through the first 21 days,
corresponding to the phase of exponential replication that
precedes the onset of a full adaptive immune response. By days
70 and 168, during the chronic phase of the infection, the bacterial
burden in lungs, liver and spleen of the PKR-deficient strain was
4- to 10-fold lower than in the wild type (Figure 1A). In 5
independent experiments—4 using C57BL/6J mice and one using
129S1/SvImJ mice as the wild type strain– the CFU in lungs of
PKR-deficient mice were 2.7-, 3.6-, 13.9-, 41.8-fold and 4.6-fold
(mean, 13-fold) lower than in wild type mice at the latest time
point studied in each experiment (Days 84, 112 or 168) (Figure 1B).
The improved control of Mtb in PKR-deficient mice was
statistically significant (p,0.001 by Wilcoxon’s matched pair test).
We assessed the extent of pathology in Mtb-infected, PKR-
deficient mice compared to that in wild type mice to see if the
reduced bacterial burden might have resulted from recruitment of
larger numbers of more destructive immune and inflammatory
cells or, conversely, may have resulted in fewer immune or
inflammatory cells being attracted or retained. We prepared 5
sections evenly spaced through each fixed lung from all mice 24
weeks after infection with Mtb in the experiment shown in
Figure 1A. Two observers assigned each hemotoxylin and eosin-
stained section a score as follows: 0=no areas of diffuse or
consolidated infiltration (normal histology); 1=1–3 areas of diffuse
infiltration or consolidation by cells with the morphology of
monocytes, macrophages, epithelioid macrophages or lympho-
cytes, each such area having a diameter ,10% of the long axis of
the lung section; 2=1–2 areas of consolidation each with a
diameter .10% of the long axis of the lung section (‘‘large’’
consolidation); 3=3–5 areas of large consolidation; 4=4–15 areas
of large consolidation; 5=.15 areas of large consolidation. In the
wild type mice, the scores averaged 2.760.3 (mean 6 SE). In the
PKR-deficient mice, the scores averaged 1.460.2. The difference
was statistically significant (p,0.05 by Mann Whitney’s two-tailed
U-test). Figure 1C shows sections that scored close to the mean for
each genotype. PKR-deficient lungs also revealed fewer Mtb
visible by acid-fast staining (Figure 1D).
The phenotype of improved control of Mtb infection by PKR-
deficient mice over many months during the chronic phase of the
infection was not recapitulated in macrophages that were
differentiated from bone marrow in vitro and studied in isolation
for several days. In vitro, the extent of uptake of Mtb over 4 hours
and its subsequent intracellular growth without IFN-gamma or
lack of growth in the presence of IFN-gamma over 3 days were
indistinguishable in macrophages derived from wild type and
PKR-deficient mice (Figures 1E and 1F). This suggested that in
vitro studies on such macrophages could reveal only limited
aspects of phenomena involving multiple cell types, physiologic
environments and long periods of time in vivo. At the same time,
however, these findings suggested that comparisons of macro-
phages in vitro from wild type and PKR-deficient mice would not
be confounded by dissimilar loads of Mtb.
Impact of PKR Deficiency on Apoptosis of Mtb-Infected
Macrophages
Among the major processes by which macrophages control Mtb
are apoptosis [28,29] and the expression of iNOS and TNF-alpha.
To test for an apoptotic phenotype in vivo, lung sections from
Mtb-infected wild type and PKR-deficient mice were stained by
TUNEL to identify apoptotic cells and with an antibody to identify
macrophages. By day 70, when Mtb infection was well advanced,
the proportion of apoptotic macrophages was 2.8-fold higher in
the lungs of PKR-deficient mice than wild type. The pro-apoptotic
phenotype persisted through at least day 168, with a 2.1-fold
higher proportion of apoptotic macrophages in the PKR-deficient
mice (Figure 2A). We confirmed the pro-apoptotic phenotype of
Mtb-infected, PKR-deficient macrophages using bone marrow
derived macrophages in vitro, as judged both by TUNEL staining
(Figure 2B) and by an ELISA for cytoplasmic histone-associated
DNA (Figure 2C). The greater apoptotic response of PKR-
deficient macrophages than wild type macrophages to Mtb
infection was associated with markedly decreased expression of
the anti-apoptotic proteins Bcl-x and Bcl-2 (Figure 2D). Because it
will be shown below that PKR-deficient macrophages produce
more TNF than wild type macrophages in response to IFN-
gamma, it was important to test if the exaggerated apoptotic
phenotype of PKR-deficient, Mtb-infected macrophages might be
influenced by their production of TNF-alpha. However, the
increased level of apoptosis persisted in the presence of
neutralizing antibody to TNF-alpha (Figure 2E).
Impact of PKR Deficiency on Production of Reactive
Nitrogen Intermediates
Because control of tuberculosis in mice depends on expression
of iNOS [30], we tested whether improved control in PKR-
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e30512Figure 1. Course of Mtb infection in PKR-deficient and wild type mice. (A) Time course of burden of colony-forming units (CFU) in lung, liver
and spleen over 24 weeks following infection by inhalation of an average of 30 CFU by wild type mice and 37 CFU by PKR-deficient mice. Results are
means 6 SD for 5 mice per time point. Asterisks mark time points at which the differences had p values#0.01 by Student’s t test. (B) Mtb burdens
(mean CFU 6 SEM for 4–6 mice per strain) in lungs of mice from 5 independent experiments at the latest time point post-infection evaluated in each
experiment. Red bars: PKR
2/2 mice. Blue bars: C57LB/6 wild type controls. Green bar: 129S1/SvImJ wild type controls. The initial bacterial burdens
were comparable between mouse strains within each experiment as assessed by the following CFU counts 24 hours post infection (pairs are means
for wild type mice followed by PKR-deficient mice in individual experiments in the order depicted in the figure): 30, 37; 15, 20; 24, 22; 488, 468; 40, 45.
The unusually low CFU seen in the first experiment are depicted with reference to an expanded Y-axis. (C and D) Histopathology (C) and acid-fast
staining of Mtb (D) in lungs from Mtb-infected wild type and PKR
2/2 mice at day 168 from a representative experiment. (E and F) Comparable uptake
and control of Mtb by PKR-deficient and wild type macrophages in vitro. (E) Uptake of Mtb 4 hours after addition at the indicated MOI, with and
without exposure of macrophages to IFN-gamma (10 ng/mL) overnight in advance of infection. (F) Intracellular growth of Mtb (MOI=3) with and
without exposure of macrophages to IFN-gamma (10 ng/mL) overnight in advance of infection. With the other MOIs tested (1 and 10), there was
likewise no significant difference in the numbers of CFU in PKR-deficient and wild type macrophages over the 3 days studied.
doi:10.1371/journal.pone.0030512.g001
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intermediates (RNI). To assess this at the level of product
formation, we measured nitrite and nitrate, the accumulating
autoxidation products of NO, in the serum of Mtb-infected mice at
day 168 post-infection. In two independent experiments, the level
of these RNI was about twice as high in serum from PKR-deficient
mice as from wild type mice (p,0.0005 by unpaired t test)
(Figure 3A), despite the lower burden of bacteria to serve as a co-
inducer of iNOS expression [11].
We used bone marrow derived macrophages in vitro to
investigate the mechanisms for the in vivo phenotype of Mtb-
infected, PKR-deficient mice. As noted, induction of iNOS in
mouse macrophages in vitro usually requires two signals—a
cytokine such as IFN-gamma and a microbe or microbial product
Figure 2. Enhanced apoptosis of the PKR-deficient macrophages. (A) Apoptosis of macrophages in vivo. After 70 or 168 days of infection,
sections of lungs from 5 WT and 5 PKR
2/2 mice were stained by TUNEL and with an anti-macrophage antibody, AIA [58]. TUNEL-positive
macrophages were counted in 4 microscopic fields per lung in areas of comparable histopathology such that approximately 20–40 TUNEL-positive
cells were evaluated per mouse. **, p,0.005, ***; p,0.0005 (unpaired t test). (B) Apoptosis of macrophages in vitro assessed by TUNEL. Macrophages
(5610
4) from wild type and PKR
2/2 mice were incubated with or without IFNc (10 ng/mL) overnight and then infected with Mtb at MOI 10. After
24 h, apoptosis was assayed by counting the proportion of TUNEL-positive macrophages in 4 microscopic fields per well. Control, no Mtb. ***,
p#0.0005 (unpaired t test). NS, not significant. (C) Apoptosis of macrophages in vitro assessed by ELISA for cytoplasmic histone-associated mono-
and oligo-nucleosomes. Macrophages were infected as in (B). The relative extent of apoptosis is presented as a ratio of absorbance values from
infected macrophages to those from uninfected macrophages. In (B) and (C), results are means 6 SD for 3 replicates in one experiment representative
of 2. (D) Western blot for apoptosis-inhibitory proteins at the indicated times after infection of macrophages with Mtb at MOI=1. Immunoblot for b-
tubulin served as a loading control. (E) Effect of anti-TNF-alpha on apoptosis of primary macrophages in response to Mtb infection. Macrophages
from WT and PKR
2/2 mice were incubated with or without IFN-gamma (10 ng/mL) overnight and then treated with anti–TNF-alpha IgG (10 mg/mL)
or isotype-matched irrelevant IgG just before the infection with Mtb at MOI 10 for 24 hr. Apoptosis was assayed by staining with TUNEL and
quantified as the percentage of TUNEL positive cells among DAPI positive cells. Data are means 6 SD for 4 fields of cells for each condition.
doi:10.1371/journal.pone.0030512.g002
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e30512Figure 3. Enhanced expression of iNOS in PKR-deficient mice and macrophages in response to Mtb and IFN-gamma. (A) Nitrite plus
nitrate in sera from Mtb-infected wild type and PKR-deficient mice. Nitrite and nitrate in serum from Mtb-infected mice at day 168 were measured by
the Griess reaction after nitrate was reduced to nitrite as described [30]. Means 6 SD of 4–5 mice in one experiment representative of two. ***,
p,0.0005 (unpaired t test). (B) Secretion of nitrite by macropahges in vitro. Macrophages (5610
5) were treated with Mtb (MOI 3), IFN-gamma (10 ng/
mL), or pre-treated with IFN-gamma (10 ng/mL) overnight followed by infection with Mtb (MOI 3) for 24 h. Nitrite in the supernatant was determined
by the Griess reaction. Means 6 SD of triplicates. (C and D) Mature and nascent iNOS transcripts. Macrophages were incubated as in (B) for 3 h. qRT-
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experiments. PKR-deficient macrophages responded to the
combination of Mtb and IFN-gamma with higher levels of
unspliced iNOS transcripts, mature iNOS transcripts and iNOS
protein than wild type macrophages (Figure 3B–D). Strikingly,
however, PKR-deficient but not wild type macrophages also
expressed iNOS in response to IFN-gamma alone (Figure 3D and
E). Induction of iNOS by IFN-gamma as sole stimulus in PKR-
deficient macrophages was both transcriptional (Figure 3D) and
post-transcriptional (Figure 3F). The estimated t1/2 of iNOS
mRNA in IFN-gamma -treated WT macrophages was 2 hr, while
the t1/2 of iNOS mRNA in PKR
2/2 macrophages was prolonged
to 6–8 hr. Thus, PKR suppressed both the transcription and the
stability of iNOS mRNA in IFN-gamma –treated macrophages.
Impact of PKR Deficiency on Production of TNF-alpha
Two cytokines are known to be critical for humans to control
tuberculosis: IFN-gamma, as judged by the predisposition to
mycobacterial infection in people with genetic deficiency states in
proteins involved in IFN-gamma production and signaling [31],
and TNF-alpha, as revealed by the risk of reactivation of latent
tuberculosis infection in people given therapeutic agents that
neutralize TNF-alpha in the treatment of inflammatory diseases
[32]. Accordingly, we tested the production of TNF-alpoha in vivo
and in vitro. In four of five independent experiments in Mtb-
infected mice, levels of TNF-alpha were significantly higher in
homogenates of the PKR-deficient lungs than in wild type lungs,
despite the lower bacterial burden in the PKR-deficient lungs
(Figure 4A). In vitro, IFN-gamma alone was sufficient to induce
TNF-alpha at the transcriptional level in PKR-deficient but not
wild type macrophages (Figure 4B, C).
Role of IL-10 in PKR-mediated Inhibition of Macrophage
Activation
PKR has been reported to mediate IL10 induction in
macrophages in response to dsRNA, LPS and Sendai virus [24].
When produced by a population of macrophages, IL10 can
potently suppress the expression of iNOS and TNF-alpha in the
Figure 4. Enhanced expression of TNF-alpha in PKR-deficient mice and macrophages. (A) Levels of TNF-alpha in lung homogenates. TNF-
alpha in lung homogenates from Mtb-infected mice at indicated time was measured by ELISA. Means 6 SD for 4 mice per strain from one experiment
representative of four. *, p,0.05, **, p,0.005, (unpaired t test). (B) Nascent TNF-alpha transcripts. Macrophages (5610
5) were incubated with the
indicated concentrations of IFN-gamma for 3 h. qRT-PCR signals for TNF-alpha were normalized to GAPDH. Means 6 SD of triplicates. (C) Secretion of
TNF-alpha. Macrophages (5610
5) were incubated with the indicated concentrations of IFN-gamma for 48 h. Supernatant was collected for TNF-alpha
production by ELISA. Means 6 SD of triplicates. In (B) and (C), results are from one of two similar experiments.
doi:10.1371/journal.pone.0030512.g004
PCR signals for iNOS were normalized to GAPDH. Means 6 SD of triplicates. In (B), (C) and (D), results are from one of two similar experiments. Results
were similar in additional experiments at MOI’s of 0.3, 1 and 3 and IFN-gamma concentrations of 1, 10 and 100 ng/mL. (E) Western blot (left) and its
densitometric assessment (right) for iNOS in macrophages incubated with the indicated concentrations of IFN-gamma for 24 h. Immunoblot for beta-
tubulin served as a loading control. (F) Impact of PKR deficiency on stability of iNOS mRNA. Macrophages were treated with IFN-gamma (10 ng/mL)
followed 3 h later by actinomycin D (10 micrograms/mL). RNA was extracted at the indicated times for RT-PCR and normalized to GAPDH.
doi:10.1371/journal.pone.0030512.g003
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production by Mtb-infected bone marrow-derived macrophages.
Mtb infection induced about twice as much IL10 in wild type as in
PKR-deficient macrophages (Figure 5A). IFN-gamma is well
known to reduce production of IL10, not induce it. As expected,
IFN-gamma reduced the levels of IL10 induced by Mtb
(Figure 5A). In contrast, to our surprise, IFN-gamma alone
induced low levels of IL10 in uninfected wild type macrophages,
and not in PKR-deficient cells (Figure 5A). Induction of IL10 by
IFN-gamma in wild type macrophages was manifest by increases
in nascent and mature transcripts as well as secreted protein
(Figure 5B).
When IL10 was added to IFN-gamma-treated PKR-deficient
macrophages, nascent iNOS transcripts, nitrite, nascent TNF-
alpha transcripts and TNF-alpha protein were all reduced to the
level of wild type cells (Figure 5C–D). The amounts of reagent
IL10 required to phenocopy wild-type behavior in IFN-gamma-
treated PKR-deficient macrophages were higher than those
released by wild type macrophages in response to IFN-gamma.
This may reflect lower specific activity of the recombinant protein
than the natural protein, or the involvement of an additional
cytokine besides IL10. Conversely, when anti-IL10 neutralizing
antibody was added to IFN-gamma-treated wild type macrophag-
es, their production of nitrite rose 22.5-fold, while production of
nitrite rose only 2.6-fold in PKR-deficient macrophages
(Figure 5E). Thus, PKR represses IFN-gamma-dependent macro-
phage activation by mediating compensatory IL10 production.
Effect of a PKR Inhibitor on Macrophage Activation in
vitro
A novel PKR inhibitor was recently identified that can inhibit
the enzyme within intact macrophages at mid-micromolar
concentrations [33]. When applied to wild type macrophages,
the inhibitor, N-(2(1H-indol-3-yl)ethyl)-4-(2-methyl-1H-indol-3-yl)-
pyrimin-2-amine (Figure 6A), partially phenocopied PKR defi-
ciency in promoting nitrite release (Figure 6B) and suppressing
IL10 release (Figure 6C) in response to IFN-gamma. Both
promotion of nitrite release and the morphologic integrity of the
macrophages (not shown) demonstrated that the inhibitor was not
toxic under the conditions tested. These observations suggested
that PKR’s role in promoting IL10 release and suppressing
macrophage activation depended on its enzyme activity.
Activation of PKR by IFN-gamma
There has been little evidence that IFN-gamma activates PKR
[34], but our results strongly suggested that this is the case in
macrophages. In fact, as shown in Figure 7A, PKR was rapidly
phosphorylated in IFN-gamma-treated macrophages. Because
PKR affected IFN-gamma-induced transcription of iNOS, TNF-
alpha and IL10, we considered that IFN-gamma might trigger the
translocation of PKR to the nucleus, where it could phosphorylate
proteins participating in transcriptional control. However, confo-
cal immunofluorescence microscopy demonstrated that all detect-
able PKR was cytosolic and remained so with and without
exposure of the macrophages to IFN-gamma and/or infection by
Mtb. Specificity of the staining was confirmed by its absence in
PKR-deficient cells (Figure 7B). Thus, PKR probably acts in the
cytosol to mediate aspects of IFN-gamma signaling. We detected
no differences in the phosphorylation of ERK1/2, p38, STAT1 or
STAT3 in response to IFN-gamma in wild type and PKR-
deficient macrophages (Figure S1). However, the binding of
STAT1 to an IFN-gamma-activated site (GAS) from the iNOS
promoter was diminished in extracts from the nuclei of IFN-
gamma-activated, PKR-deficient macrophages compared to wild
type (Figure S2).
Discussion
PKR deficiency led to reduced bacterial burden and reduced
pathology in mice with tuberculosis. Macrophages in the lungs of
PKR-deficient mice showed more extensive apoptosis than in wild
type mice and PKR-deficient mice accumulated higher levels of
RNI in their blood. In vitro, PKR-deficient macrophages
underwent more extensive activation than wild type macrophages
in response to IFN-gamma alone or the combination of exposure
to IFN-gamma and infection with Mtb. A major mechanism at
work was the IFN-gamma-mediated activation of PKR in wild
type macrophages, leading to induction of IL10. IL10 acted to
restrain the extent to which macrophages produced iNOS and
TNF-alpha, two critical mediators of host control of tuberculosis.
Our studies do not establish to what extent the IL10-dependent
mechanisms uncovered in vitro account for the in vivo phenotype
of PKR-deficient mice during Mtb infection. However, the
observations reported here do implicate the enzymatic action of
PKR, because a PKR inhibitor phenocopied key aspects of the
PKR-deficient phenotype in vitro. Very few PKR inhibitors have
been reported and none have undergone the structural optimiza-
tion or mechanistic and pharmaceutical characterization that
could qualify them for testing in mice [33]. However, the present
observations suggest that PKR inhibitors with the requisite
potency, selectivity and bioavailability should be developed for
tests of efficacy in experimental tuberculosis. The candidacy of
PKR as a therapeutic target has been suggested in a number of
other diseases, including neurodegeneration, obesity, diabetes and
influenza [26,35,36,37,38,39].
The enhanced apoptosis of PKR-deficient macrophages upon
Mtb infection may have contributed substantially to improved
control of the infection [40]. Genetic evidence in both the host
[41] and the pathogen [42,43] supports the importance of
apoptosis as a means of limiting Mtb’s virulence and promoting
its immunogenicity. PKR has different effects on apoptosis and
activation in various cells and situations [23]. PKR was required
for mouse macrophages to undergo apoptosis in response to the
TLR4 agonists LPS, B. anthracis, S. enterica var. Typhimurium and Y.
pseudotuberculosis, particularly when p38 was pharmacologically
blocked [44]. However, Mtb predominantly stimulates TLR2
[45,46] rather than TLR4, and p38 inhibitors were not used in our
experiments. These differences may help explain why we found
that PKR restrained, rather than promoted, apoptosis in Mtb-
infected macrophages. In the study of Hsu et al., iNOS induction
by LPS was impaired in PKR-deficient macrophages [44].
Similarly, neither LPS nor poly-IC could induce iNOS in PKR-
deficient mouse embryonic fibroblasts [47]. In our hands, when
used as a sole stimulus, LPS alone and IFN-gamma alone each
induce little or no iNOS in wild type macrophages. In contrast,
IFN-gamma used as sole stimulus induced abundant iNOS in
macrophages that lacked PKR. Moreover, the combination of
IFN-gamma and Mtb induced more iNOS in PKR-deficient
macrophages than in wild type cells. Thus, depending on the
stimuli, PKR can either promote or restrain classical macrophage
activation. With IFN-gamma and Mtb as stimuli, the predominant
action of PKR appears to be to restrain macrophage activation by
enabling the induction of counter-regulatory IL10.
That PKR can help mediate IFN-gamma signaling has been
suggested, but to our knowledge, this had not previously been
demonstrated by altered expression of an IFNc-induced protein in
the absence of another stimulus. For example, compared to wild
PKR Deficiency and Macrophage Activation
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2/2 embryonic fibroblasts responded to IFN-gamma
withless phosphorylation of p38 [48] and STAT1 [49] and with less
activation of NF-kappaB [50] and IRF1 [47] in electrophoretic
mobility shift assays, but effects on protein expression were not
described. In macrophages, we did not detect an effect of PKR on
phosphorylation of p38 or STAT1 in response to IFN-gamma, and
IFN-gamma did not appear to activate NF-kappaB (not shown).
PKR has been reported to mediate IL10 induction in
macrophages in response to dsRNA, LPS and Sendai virus [24].
However, it has apparently not been appreciated that IFN-gamma
can induce low-level IL10 expression in macrophages, or that
PKR is required for this response. To the contrary, it is well
established that IFN-gamma suppresses IL10 expression in
response to another agonist [51,52]. That IFN-gamma can have
both actions is consistent with emerging evidence that pro-
inflammatory stimuli often induce their own antagonists [53]. The
ability of T cell clones to produce IFN-gamma and IL10
simultaneously is well accepted as a mechanism by which the
host can both induce and restrain immune responses [54]. The
ability of macrophages to respond to IFN-gamma by making small
amounts of IL10 can be seen in the same light.
Specifically, we found that IFN-gamma blunted the induction of
IL0 by Mtb in infected macrophages, yet induced a small amount of
IL10 by itself in uninfected macrophages. Most macrophages in
tuberculosis lesions do not contain Mtb, yet they are exposed to
the same cytokines as the macrophages that are infected.
Immunopathology would be reduced if the uninfected macro-
phages were to undergo less activation than the infected ones.
Induction of low levels of IL10 by IFN-gamma in uninfected
macrophages could serve to temper, without preventing, the pro-
inflammatory effects of IFN-gamma. The evolved function of such
a circuit is presumably to reduce immunopathology during
Figure 5. Induction of IL-10 by Mtb and IFN-gamma and its impact on iNOS and TNF-alpha. (A) Secretion of IL-10. Macrophages (5610
5)
were treated with Mtb (MOI 3), IFN-gamma (10 ng/mL), or pre-treated with IFN-gamma (10 ng/mL) overnight followed by infection with Mtb (MOI 3)
for 24 h. Supernatant was collected for IL-10 production by ELISA. Results were similar in additional experiments with MOIs of 0.3, 1 and 3 and IFN-
gamma concentrations of 1, 10 and 100 ng/mL. (B) Induction of mature and nascent IL-10 transcripts. Macrophages (5610
5) were treated with IFN-
gamma (10 ng/mL) for 3 h. qRT-PCR signals for IL-10 were normalized to GAPDH. Results were similar with IFN-gamma concentrations of 1, 10 and
100 ng/mL. (C) Effect of IL-10 on nascent iNOS transcripts and secretion of nitrite. Left panel, macrophages (5610
5) were treated with IL-10 for 3 h
after the addition of IFN-gamma 0 ng/mL. qRT-PCR signals for iNOS were normalized to GAPDH. Right panel, macrophages (5610
5) were treated with
IL-10 for 48 h after the addition of IFN-gamma 0 ng/mL. Nitrite in the supernatant was measured by the Griess reaction. (D) Effect of IL10 on nascent
TNF-alpha transcripts and TNF-alpha. Left panel, macrophages (5610
5) were treated with IL-10 for 3 h after the addition of IFN-gamma 0 ng/mL. qRT-
PCR signals for TNF-alpha were normalized to GAPDH. Right panel, macrophages (5610
5) were treated with IL-10 for 48 h after the addition of IFN-
gamma 0 ng/mL. TNF-alpha in the supernatant was measured by ELISA. (E) Effect of neutralizing anti-IL-10 antibody (10 mg/mL) on release of nitrite
48 h after addition of IFN-gamma (10 ng/mL). Results in (A) to (F) are means 6 SD from individual experiments each with 3 replicates that are
representative of at least 2 independent experiments.
doi:10.1371/journal.pone.0030512.g005
Figure 6. A PKR inhibitor partially phenocopies the effect of PKR deficiency on release of nitrite and IL10 in response to IFN-
gamma. (A) Structure of the PKR inhibitor N-(2(1H-indol-3-yl)ethyl)-4-(2-methyl-1H-indol-3-yl)pyrimin-2-amine. (B) Impact of the inhibitor on nitrite
release 48 h after addition of IFN-gamma (10 ng/mL) to wild type macrophages. (C) Impact on IL10 secretion 48 h after addition of IFN-gamma
(10 ng/mL) to wild type macrophages. (B) and (C) are means 6 SD for 3 replicates in one of 3 similar experiments.
doi:10.1371/journal.pone.0030512.g006
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apparently led to enough of a reduction in bacterial burden to
avoid the risk of enhanced immunopathology.
PKR was not identified as an Mtb-related CGEP in RNAi
screens that targeted all kinases [6] or all genes [7] in macrophage
cell lines. In retrospect, this is not surprising, because we found
that PKR deficiency had no effect on the ability of macrophages to
take up Mtb or restrain its growth in vitro (data not shown). It is
not clear why PKR deficiency was associated with reduced growth
of Mtb in vivo but not in vitro. In general, macrophage control of
Mtb in vitro appears to be far less effective than in the host [55].
In conclusion, to our knowledge, the present report appears to
be the first to identify a host enzyme whose absence is beneficial
during infection of the host with Mtb.
Materials and Methods
Ethics Statement
Mice were studied under a protocol (#0512-422) approved by
the Weill Cornell Medical College Institutional Animal Care and
Use Committee.
Mtb
We grew Mtb strain H37Rv to early log phase in Middlebrook
7H9 broth (BD Biosciences) with BBL Middlebrook OADC
Enrichment (Becton Dickinson) and 0.05% (vol/vol) Tween 80
(Sigma-Aldrich). Predominantly single-cell suspensions were col-
lected by centrifuging twice at 125 g, resuspending in PBS with
0.05% Tween 80 and using the supernate from 10 min
centrifugation at 125 g to infect macrophages or mice.
Mice and Macrophages
Young adult female C57BL/6 and 129S1/SvImJ mice were
from Jackson Laboratories. PKR
2/2 mice were interbred locally
from founders kindly provided by Prof. Charles Weissmann
(University of Zurich) [56]. PKR was undetectable in primary
bone marrow-derived macrophages from these mice, as judged by
western blot and poly IC-stimulated kinase activity (Figure S3).
Tail biopsies were lysed in 500 ml 50 mM Tris-HCl (pH 8.0),
100 mM EDTA, 100 mM NaCl, 1% SDS, and 0.1 mg/mL
proteinase K at 56uC overnight. DNA was precipitated with one
volume of isopropanol, washed with cold 70% ethanol and 100%
ethanol and dissolved in TE buffer (10 mM Tris-HCl, 1 mM
EDTA, pH 8.0). PCR primers complementary to the neomycin
cassette NeoF (59-39) CAGGTAGCCGGATCAAGCGTATGC
and NeoR (59-39) CCTGTCCGGTGCCCTGAATGAACT gen-
erated a 200-bp fragment. Primers corresponding to PKR intron 1
and intron 3, PkrF-1 (59-39) AGCGGCCCTGTCTCCTGTTCT
and PkrR-1 (59-39) TGCTGGGGGAGTGGATTGCG, generat-
ed a 543-bp fragment. The PCR reaction in a GeneAmp PCR
Figure 7. Activation of PKR by IFN-gamma. (A) Autophosphorylation of PKR in macrophages at the indicated times after addition of IFN-gamma
(10 ng/mL). A duplicate gel western blotted with antibody to beta-tubulin served as a loading control. One of four similar experiments. (B)
Immunofluorescent localization of PKR in wild type macrophages with and without Mtb infection and/or IFN-gamma treatment. Macrophages from
wild type and PKR
2/2 mice were incubated with or without IFN-gamma (10 ng/mL) at 37uC overnight and then infected with Mtb at MOI 10 for 24 h.
Macrophages were fixed with 4% p-formaldehyde for 2 h and immunofluorescent staining for PKR (green) and DNA (DAPI; blue) was conducted.
Images were recorded by confocal microscopy.
doi:10.1371/journal.pone.0030512.g007
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66uC4 0s ,7 2 uC 1 min. PCR products (15 ml) were electropho-
resed on a 1.8% agarose gel, stained with ethidium bromide and
visualized by UV illumination.
WT and PKR
2/2 mice were infected with early log phase
cultures of Mtb H37Rv by aerosol using a Glas-Col Inhalation
Exposure System (Glas-Col Inc.). At indicated times, mice were
euthanatized by CO2 inhalation. The initial inoculum was
enumerated by collecting lungs from members of the cohort
24 hr post-infection. Serum was collected for RNI determination
and lungs were homogenized in PBS. A portion of the homogenate
was reserved for ELISAs. The remainder was serially diluted and
plated on Middlebrook 7H11 agar plates (BD Biosciences). CFU
were counted after 21days.
For in vitro experiments, bone marrow cells were flushed from
femurs and differentiated for 6 days in 150615 mm petri dishes in
DMEM containing 0.29 g/L L-glutamine, 1 mM sodium pyru-
vate, 10% FBS and 20% L929 fibroblast-conditioned medium.
Macrophages were resuspended by incubation in 1 mM EDTA in
PBS for 10 min on ice, washed twice with PBS and plated into 24-
or 48-well tissue culture plates (Corning). Purified recombinant
mouse IFN-gamma, TNF-alpha and IL10 were from R&D
Systems. The PKR inhibitor N-(2(1H-indol-3-yl)ethyl)-4-(2-meth-
yl-1H-indol-3-yl)pyrimin-2-amine [33] was initially purchased
from Villapharma and subsequently synthesized in the Milstein
Chemistry Core Facility at Weill Cornell Medical College.
Assays for Cytokines and RNI
Macrophages (5610
5 in 1 mL of complete DMEM containing
10% L-cell-conditioned medium) were seeded into 24-well tissue
culture plates, treated with or without IFN-gamma (10 ng/mL)
and infected or not with Mtb at the indicated MOIs. Supernatants
were tested for IL10 and TNF-alpha using a Duoset ELISA (R&D
Systems). Nitrite was detected by mixing an aliquot of superna-
tants with an equal volume of Griess’s reagent (1% sulfanilamide,
0.1% naphthylethylenediamine dihydrochloride, 2.5% H3PO4).
Absorbance at 550 nm was measured with sodium nitrite as
standard. Nitrite content of cell-free medium was subtracted. For
assays on serum from Mtb-infected mice, nitrite and nitrate were
measured by the Griess reaction after nitrate was reduced to nitrite
as described [30].
Western Blot
Macrophages (5610
6) were seeded in 6-well tissue culture plates,
pre-treated or not overnight with IFN-gamma (10 ng/mL) and
infected or not with Mtb at stated MOIs. At the indicated time,
macrophages were lysed and boiled in reducing SDS-PAGE sample
buffer containing 100 mM Tris, pH 6.8, 4% SDS, 5% beta-
mercaptoethanol,20%glyceroland0.2%bromophenolblue.Lysates
was subjected to 4–15% gradient gel electrophoresis (Bio-Rad) and
transferred to a 0.2 micron pore nitrocellulose membrane (Schleicher
& Schuell) in 20% methanol, 25 mM Tris and 192 mM glycine,
pH 8.3 and 0.1% SDS. Anti-PKR Ab (sc-1702) for western blot was
from Santa Cruz Biotech. Anti-iNOS Ab was from Abcam.
Detection was by the Odyssey system (LI-COR Biosciences).
Real-Time Quantitative RT-PCR
Qiagen furnished RNA extraction kits. Invitrogen synthesized
oligonucleotide primers and Biosearch Technologies provided
probes labeled with fluorescent amidites (FAM) at the 59 end and
Black Hole Quencher (BHQ) at the 39 end. Primers and probe
sequences for mature iNOS were TGCTCCCTTCCGAAG-
TTTCTG (forward), TCATGCGGCCTCCTTTGAG (reverse),
and AGCAGCGGCTCCATGACTCCCAG (probe). Primers and
probe sequences for mature IL10 were AGACCCTCAG-
GATGCGGC (forward), CCACTGCCTTGCTCTTATTTTCA
(reverse), and AGGCGCTGTCATCGATTTCTCCCCT (probe).
Primers and probe sequences for mature TNF-alpha were GG-
CCTCCCTCTCATCAGTTCT (forward), GTGGGCTACAG-
GCTTGTCA (reverse), and TGGCCCAGACCCTCACACT-
CAG (probe). Primers and probe sequences for GAPDH were
GGGCATCTTGGGCTACACT (forward), GGCATCGAAGG-
TGGAAGAGT (reverse), and AGGACCAGGTTGTCTCCT-
GCGA (probe). Primers and probe sequences for nascent iNOS
were CTCACGCTTGGGTCTTGTTCA, (forward), CCAAG-
CAGGAAGACACTCCTAAG (reverse), and AGTAGCCTAGT-
CAACTGCAAGGTGAGTC (probe). Primers and probe sequenc-
es for nascent IL10 were CAGAGCCACATGCTCCTAGAG
(forward), TCAGGTGATGGCAGGAAGAAAG (reverse), and
CGGACTGCCTTCAGCCAGGT (probe). The primers and
probe sequences for nascent TNF-alpha were CACCACGCTCT-
TCTGTCTACTG (forward), CTGTCCTTCTTGCCCTCCT-
AAC(reverse),andTGATCGGTCCCCAAAGGGATGA(probe).
100–300 ng RNA was transcribed into cDNA with oligo d(T) in 20
microL using MulLV reverse transcriptase (Applied Biosystems).
cDNAwasdilutedto200microL.WeperformedPCRin15microL
in an ABI PRISM 7900HT sequence detection system and
normalized results to GAPDH.
mRNA Stability
Primary macrophages were seeded in 24-well tissue culture
plates overnight, then stimulated with IFN-gamma (10 ng/mL).
Actinomycin D (Sigma-Aldrich) was added 3 h later. Total RNA
was extracted at indicated times and transcribed into cDNA with
oligo d(T) using MulLV reverse transcriptase (Applied Biosystems).
cDNA was amplified by PCR using Taq DNA polymerase (New
England BioLabs) and PCR products were analyzed by agarose gel
electrophoresis. Primers for iNOS were AGTATAAGGCAAG-
CACCTTGG (forward) and GCTCTGGATGAGCCTATA-
TTGC (reverse). Primers for IL10 were GAAGACAATAACTG-
CACCCACT (forward) and TTCATGGCCTTGTAGACACCT
(reverse). Primers for TNFa were GACGTGGAACTGGCA-
GAAG (forward) and CAGCCTTGTCCCTTGAAGAG (re-
verse). The primers for GAPDH were TGGAGATTGTTGC-
CATCAACG (forward) and AAGTTGTCATGGATGACCT-
TGG (reverse). Results were normalized to GAPDH.
Immunocytology
Primary macrophages were mounted on nitric acid-treated
coverslips, pretreated or not with IFN-gamma (10 ng/mL)
overnight and then infected or not with Mtb for 24 h.
Macrophages were fixed for 2 h with 4% (vol/vol) paraformalde-
hyde in PBS and permeabilized for 30 min at room temperature
with 0.2% saponin in PBS containing 10% (vol/vol) donkey
serum. Coverslips were incubated for 30 min at room temperature
with anti-PKR antibody (dilution, 1:50). Cells were rinsed twice
with PBS containing 0.2% saponin and stained for 1 h at room
temperature with secondary antibody conjugated with Alexa
fluor
TM 488 (Molecular Probes) (dilution, 1:500). Coverslips were
washed twice with PBS containing 0.2% saponin, once in ddH2O
and mounted on slides. Images were acquired with an inverted
LSM 510 Laser scanning confocal microscope [57] at the
Rockfeller University Bio-Imaging Resource Center.
Apoptosis Assays
Apoptosis of macrophages in vitro was evaluated by TdT-
mediated dUTP nick-end labeling (TUNEL) using TMR red in-
situ cell death detection and by Cell Death Detection ELISA
PLUS
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4 primary macrophages
per well were seeded into 48-well plates and treated or not with
10 ng/mL of IFN-gamma overnight. Cells were infected with Mtb at
MOI 10 for 24 h, fixed with 2% paraformaldehyde in PBS for 2 h,
permeabilized with 0.1% Triton x-100 in 0.1% sodium citrate for
2 min on ice and incubated in TdT reaction mixture containing
TMR red dUTP for 1 h at 37uC in a dark, humidified chamber.
Total cell number was assessed by following incubation with 49,6-
diamidino-2-phenylindole(DAPI)for5 min.Thecellswereviewedat
room temperature using an Olympus IX-70 inverted fluorescent
microscope. The apoptosis ELISA measured cytoplasmic histone-
associated DNA fragments. Macrophages (5610
5) were incubated
with or without IFN-gamma (10 ng/mL) in 24-well plates at 37uC
overnight and then infected with Mtb at MOI 5, 10 or 20 for 24 h
before assay of cell lysates following the manufacturer’s specifications.
The relative amount of apoptosis was calculated as a ratio of the
difference in absorbance at 405 nm and 490 nm of infected
macrophages to that of uninfected macrophages.
Apoptotic macrophages in lungs of Mtb-infected mice were
identified as described [58]. Formalin-fixed, paraffin-embedded lung
sections were deparaffinized, rehydrated, treated with 0.1% Triton
X100 in PBS for 15 min at room temperature, washed with PBS,
blocked with 1.5% donkey serum in PBS for 1 h at 37uCi na
humidified chamber, incubated with 1:500 anti-macrophage
antibody (AIA, Accurate Chemical & Scientific) overnight at 4uC
and with 1:500 secondary antibody conjugated with Alexa fluor
TM
488 (Molecular Probes) for 1 h at room temperature before TUNEL
staining followed by DAPI staining. Fluorescent images were
captured by an Olympus IX-70 inverted fluorescent microscope.
PKR Autophosphorylation
The protocol used in [44] was the kind gift of Dr. Li-Chung
Hsu, National Taiwan University. Lysis buffer contained 50 mM
Tris-HCl pH 7.5, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA,
1% Triton X-100, 0.5% NP-40, 10% glycerol, 10 mM NaF and
was supplemented before use with 2 mM DTT, 1 mM PMSF,
2 mM pNPP, 20 mM beta-glycero-3-phosphate,1 mM Na3VO4
and protease inhibitor cocktail (Roche). The kinase buffer was
prepared at 106with 200 mM Tris-HCl pH 7.5, 500 mM KCl,
20 mM MgCl2, 20 mM MnCl2, and 50% glycerol. The reaction
buffer was 16 kinase buffer with 20 mM beta-glycero-3-
phosphate, 10 mM pNPP, 20 mM ATP, 1 mM DTT. Macro-
phages (1610
7) treated or not with 10 ng/mL IFN-gamma were
washed three times in PBS and lysed in 1 mL of lysis buffer for 5–
10 min at 4uC. Debris was removed by centrifugation at 13,000 g
for 10 min at 4uC and supernatant aliquotted, its protein
concentration determined by the BCA method (BioRad) and
stored at 280uC. For assay, 200 micrograms of protein per sample
was transferred to a fresh tube and brought to 400 microL in lysis
buffer. Anti-PKR Ab (10 microL) (Santa Cruz, M-515) was added
and the samples each rotated overnight with 15 mL of a 50%
slurry of protein A beads at 4uC. Immune complexes were
collected by centrifugation for 1 min at 13,000 g, washed twice in
lysis buffer and once with kinase buffer and resuspended in 25 ml
reaction buffer containing 10 microCi [gamma-P
32]-ATP. After
30 min at 30uC, reactions were stopped with 100 microL of lysis
buffer. The beads were collected by centrifugation for 1 min,
mixed with 15 microL of 26 SDS sample buffer and heated at
100uC for 5 min. The supernatants were analyzed by 4–15%
SDS-PAGE (Bio-Rad). When the dye front ran off the gel, the
bottom of the gel containing the free isotope was removed and the
gel dried for placement in a Phosphorimager.
Supporting Information
Figure S1 Lack of effect of PKR on activation of ERK1/
2, p38, STAT1 and STAT3 by IFN-gamma in primary
macrophages. Primary macrophages from wild type and
PKR2/2 mice were cultured at 37uC overnight and treated
with IFN-gamma (10 ng/mL) for 24 h. Cell lysates were separated
by SDS-PAGE and analyzed by western blotting using antibodies
against phospho-ERK1/2, phospho-p38, phospho-STAT1 and
phospho-STAT3. Beta-tubulin was used as a loading control.
(PDF)
Figure S2 PKR facilitates IFN-gamma-induced binding
of Stat1 to iNOS GAS. EMSA was performed as described in
Methods. Infrared Dye 700-labeled 15-base pair oligonucleotide
containing the iNOS GAS and 5 micrograms of nuclear extract
were used in each lane. (A) 26107 primary macrophages from
wild type and PKR2/2 mice were treated with IFN-gamma
(10 ng/mL) for the indicated time. 2, no addition of nuclear
extract. Solid arrowhead indicates Stat1-specific binding. (B)
26107 primary macrophages from wild type and PKR2/2 mice
were treated with IFN-gamma (10 ng/mL) for 15 min. 2,n o
addition of nuclear extract. +, only addition of nuclear extract. For
other lanes, the nuclear extract was pre-incubated with antibody
against Stat1, an excess of unlabeled iNOS GAS and antibody
against Stat3, respectively. Supershifted band is indicated by solid
arrowhead.
(PDF)
Figure S3 Confirmation of PKR deficiency in macro-
phages from knock-out mice. Primary macrophages were
from wild type (WT) C57BL/6 mice or PKR2/2 mice derived
from founders kindly provided by C. Weissmann (Yang et al.). (A)
Immunoblot for PKR with beta-tubulin as a loading control. (B)
Autophosphorylation of PKR at indicated times after exposure to
poly-IC (10 micrograms/mL).
(PDF)
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